NasdaqGS - Nasdaq Real Time Price USD

ICON Public Limited Company (ICLR)

308.48 +8.40 (+2.80%)
As of 2:17 PM EDT. Market Open.
Loading Chart for ICLR
DELL
  • Previous Close 300.08
  • Open 302.85
  • Bid 307.52 x 100
  • Ask 308.50 x 100
  • Day's Range 300.25 - 310.33
  • 52 Week Range 181.92 - 344.77
  • Volume 410,713
  • Avg. Volume 556,488
  • Market Cap (intraday) 25.506B
  • Beta (5Y Monthly) 1.16
  • PE Ratio (TTM) 37.39
  • EPS (TTM) 8.25
  • Earnings Date Jul 24, 2024 - Aug 3, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 353.69

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

www.iconplc.com

41,150

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ICLR

Performance Overview: ICLR

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ICLR
8.98%
S&P 500
7.06%

1-Year Return

ICLR
51.79%
S&P 500
25.41%

3-Year Return

ICLR
41.62%
S&P 500
22.16%

5-Year Return

ICLR
125.30%
S&P 500
74.51%

Compare To: ICLR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ICLR

Valuation Measures

Annual
As of 4/25/2024
  • Market Cap

    24.81B

  • Enterprise Value

    28.06B

  • Trailing P/E

    36.42

  • Forward P/E

    20.16

  • PEG Ratio (5yr expected)

    1.15

  • Price/Sales (ttm)

    3.02

  • Price/Book (mrq)

    2.63

  • Enterprise Value/Revenue

    3.46

  • Enterprise Value/EBITDA

    18.44

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.30%

  • Return on Assets (ttm)

    4.01%

  • Return on Equity (ttm)

    7.55%

  • Revenue (ttm)

    8.23B

  • Net Income Avi to Common (ttm)

    683.12M

  • Diluted EPS (ttm)

    8.25

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    398.04M

  • Total Debt/Equity (mrq)

    38.64%

  • Levered Free Cash Flow (ttm)

    1.14B

Research Analysis: ICLR

Analyst Price Targets

300.00
353.69 Average
308.48 Current
385.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: ICLR

Fair Value

308.48 Current
 

Dividend Score

0 Low
ICLR
Sector Avg.
100 High
 

Hiring Score

0 Low
ICLR
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
ICLR
Sector Avg.
100 High
 

Research Reports: ICLR

  • Analyst Report: ICON Public Limited Company

    Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

    Rating
    Price Target
     
  • Analyst Report: ICON Public Limited Company

    Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

    Rating
    Price Target
     
  • Analyst Report: ICON Public Limited Company

    Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

    Rating
    Price Target
     
  • Analyst Report: ICON Public Limited Company

    Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.

    Rating
    Price Target
     

People Also Watch